Attend PMWC 2017 Silicon Valley 3 days after the inauguration to hear from those in the know! How major will the changes be? Will we see a change in regulations, research funding, and drug or device approval? Will the oversight of different government initiatives - Cancer...
Q: What are some of the key components of the NanostringnCounter Analysis System? What are some of the advantages of the nCounter System over other analytical approaches? A: Our nCounter Analysis System unlocks massive amounts of biological information from tiny samples. The nCounter platform addresses the...
Q: Can you share with us your motivation and interest in antimicrobial resistance and development of rapid diagnostic methods for infectious disease? And why is this so important? A: We are fast approaching a time when antibiotics will no longer work and simple infections may become...
Q: Invitae wants to be the Amazon of genetic testing. What does that exactly mean and what does Invitae do that is different from other companies to achieve this? A: Invitae is proactively driving down the cost of genetic testing in order to make it more...
With the great progress we see in the field of Precision Medicine, there are still critical issues that we need to overcome whether it is the definition of value-based pricing, the successful development and application of clinical biomarkers, working in patient privacy, integrating and sharing...
Q: What attracted you to join Genomic Health and what is your role? A:Genomic Health shifted the paradigm in cancer management, helping over 700,000 patients optimize their treatment decisions, and pioneering a new business model that has been followed by many companies in the last decade....
A: I was attracted to Inivata to help progress a technology I see can make a major impact in improving how we diagnose and manage patients with cancer. The field of liquid biopsy, and ctDNA analysis specifically, is undergoing rapid development and we’re only now...
Q: What were the motivations to create the Oncology Precision Network (OPeN)? A: As we began implementing precision oncology at our hospitals and clinics throughout Intermountain Healthcare, we quickly began to realize that there are certain variants or mutations in a patient’s tumor that we may...
Does Immunotherapy Measure Up to the Hype? Brigitte Ganter, PhD Disclosures | October 27, 2016 Editor’s Note: The emergence of immunotherapy has redefined cancer medicine. Among those who continue to redefine this expanding arena of clinical research, James P. Allison, PhD, of MD Anderson Cancer Center, holds a special place....
Dr. James Allison of MD Anderson Cancer Center, considered by many to be the “father of immunotherapy” is a recipient of the PMWC 2017 Pioneer Award. In his interview published earlier this week on Medscape highlighted some of the key focus areas of PMWC 2017...
